19 completed, 7 terminated, 4 unknown, 1 not yet recruiting. 32 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 32 | Completed 19, Terminated 7, Unknown 4, Not yet recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Mycosis Fungoides: new trials by email Literature Review of Mycosis Fungoides trials Research Report on Mycosis Fungoides
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL Hypericin, Placebo - CTCL/ Mycosis Fungoides, CTCL | Phase 3 | Terminated | Soligenix | 70 | 2025-01-07 | 2026-07-13 |
| TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides Low-dose total-skin electron-beam therapy, Phototherapy - Mycosis Fungoides, Cutaneous T Cell Lymphoma | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 78 | 2022-02-01 | 2022-01-25 |
| Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides Vibramycin, Phototherapy - Lymphoma | Phase 3 | Unknown | Cairo University | 30 | 2017-03-01 | 2018-08-23 |
| Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL Naloxone Hydrochloride Lotion, 0.5%, Placebo Lotion - Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous | Phase 3 | Terminated | Elorac, Inc. | 59 | 2017-01-01 | 2022-10-28 |
| FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) SGX301 (synthetic hypericin), Placebo - Cutaneous T-Cell Lymphoma | Phase 3 | Completed | Soligenix | 169 | 2015-12-01 | 2022-04-15 |
| PUVA Maintenance Therapy in Mycosis Fungoides 8-methoxypsoralen - Patch/Plaque Stage Mycosis Fungoides | Phase 3 | Completed | Medical University of Graz | 28 | 2013-02-01 | 2018-11-14 |
| A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) Brentuximab Vedotin, Methotrexate, Bexarotene - Primary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides | Phase 3 | Completed | Millennium Pharmaceuticals, Inc. | 131 | 2012-06-11 | 2021-01-05 |
| Lenalidomide Maintenance Post-debulking in Advanced CTCL lenalidomide - Lymphoma | Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 21 | 2010-07-01 | 2018-07-09 |
| Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain ketamine hydrochloride, pharmacogenomic studies, questionnaire administration - Cancer | Phase 3 | Unknown | University of Glasgow | 214 | 2009-04-01 | 2011-05-13 |
| American Ginseng in Treating Patients With Fatigue Caused by Cancer American ginseng, placebo - Chronic Myeloproliferative Disorders, Fatigue | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 364 | 2008-10-01 | 2017-02-09 |
| Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial educational intervention - Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders | Phase 3 | Completed | Case Comprehensive Cancer Center | 583 | 2008-04-01 | 2020-07-27 |
| Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Fentanyl sublingual spray, Placebo - Cancer | Phase 3 | Completed | INSYS Therapeutics Inc | 130 | 2007-10-01 | 2014-03-05 |
| Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia amoxicillin-clavulanate potassium, ciprofloxacin, psychosocial assessment and care - Brain and Central Nervous System Tumors, Lymphoma | Phase 3 | Unknown | Clatterbridge Centre for Oncology | 400 | 2007-07-01 | 2013-08-12 |
| Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases filgrastim, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation - Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 3 | Completed | The Canadian Blood and Marrow Transplant Group | 230 | 2007-03-01 | 2014-03-05 |
| Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant moxifloxacin hydrochloride, Placebo - Breast Cancer, Chronic Myeloproliferative Disorders | Phase 3 | Terminated | OHSU Knight Cancer Institute | 240 | 2006-05-01 | 2017-05-09 |
| Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer darbepoetin alfa, ferrous sulfate, sodium ferric gluconate complex in sucrose - Anemia, Leukemia | Phase 3 | Completed | Mayo Clinic | 502 | 2006-01-01 | 2011-05-17 |
| Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome HuMax-CD4 (zanolimumab) - Mycosis Fungoides, Sezary Syndrome | Phase 3 | Terminated | Emergent Product Development Seattle LLC | 76 | 2005-07-01 | 2012-07-26 |
| Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain educational intervention, Titrated pain management, questionnaire administration - Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders | Phase 3 | Completed | Vanderbilt-Ingram Cancer Center | 98 | 2005-05-01 | 2012-09-06 |
| Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer darbepoetin alfa, epoetin alfa - Anemia, Leukemia | Phase 3 | Completed | Jonsson Comprehensive Cancer Center | 14 | 2003-08-01 | 2020-08-03 |
| Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma CHOP regimen, EPOCH regimen, cyclophosphamide - Lymphoma | Phase 2 / Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 3 | 2003-03-01 | 2012-09-24 |
Showing 20 of 32. Sign in to see all of them.
Lymphoma, T-Cell, Cutaneous (29) · Sezary Syndrome (26) · Lymphoma, Large B-Cell, Diffuse (21) · Leukemia, Lymphocytic, Chronic, B-Cell (20) · Lymphoma, Follicular (20) · Lymphoma, Large-Cell, Immunoblastic (20) · Lymphoma, Mantle-Cell (20) · Lymphoma, Non-Hodgkin (20) · Burkitt Lymphoma (19) · Hodgkin Disease (19) · Lymphoma, B-Cell, Marginal Zone (19) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (19) · Lymphoma (18) · Leukemia, Myeloid, Accelerated Phase (16)
Hemic and Lymphatic Diseases (32) · Immune System Diseases (32) · Immunoproliferative Disorders (32) · Lymphatic Diseases (32) · Lymphoma, T-Cell (32) · Neoplasms by Histologic Type (32) · Lymphoproliferative Disorders (27) · Neoplasms (24) · Hematologic Diseases (21) · Leukemia, Lymphoid (21) · Lymphoma, B-Cell (21) · Pathological Conditions, Signs and Symptoms (21) · Chronic Disease (20) · Disease Attributes (20) · Leukemia, B-Cell (20)
Cyclophosphamide (3) · Bexarotene (2) · Darbepoetin alfa (2) · Early Intervention, Educational (2) · Etoposide (2) · Levofloxacin (2) · Methoxsalen (2) · Peripheral Blood Stem Cell Transplantation (2) · Phototherapy (2) · Radiotherapy (2) · hypericin (2) · liposomal amphotericin B (2) · Acyclovir (1) · Amoxicillin-Potassium Clavulanate Combination (1) · Antilymphocyte Serum (1)
European Organisation for Research and Treatment of Cancer - EORTC (5) · Alliance for Clinical Trials in Oncology (2) · Fred Hutchinson Cancer Center (2) · Jonsson Comprehensive Cancer Center (2) · Soligenix (2) · Assistance Publique - Hôpitaux de Paris (1) · Cairo University (1) · Cancer Research Campaign Clinical Trials Centre (1) · Case Comprehensive Cancer Center (1) · Clatterbridge Centre for Oncology (1) · Elorac, Inc. (1) · Emergent Product Development Seattle LLC (1) · INSYS Therapeutics Inc (1) · Mayo Clinic (1) · Medical University of Graz (1)
United States (20) · United Kingdom (6) · Belgium (5) · France (5) · Germany (5) · Spain (5) · Austria (4) · Italy (4) · Switzerland (3) · Australia (2) · Canada (2) · Finland (2) · Hungary (2) · Israel (2) · Netherlands (2)
Barry J.A. Laird, MD (1) · Charles L. Loprinzi, MD (1) · Debra Barton, RN, PhD, AOCN, FAAN (1) · Eduardo Bruera, MD (1) · Ernest Marshall, MD (1) · Garrett Nichols, MD, MSC (1) · Jeffrey H. Lipton, MD, PhD (1) · John A. Glaspy, MD, MPH (1) · Joseph Bubalo, PharmD, BCPS, BCOP (1) · Kent Sepkowitz, MD (1) · Kieren A. Marr, MD (1) · Larry Dillaha, MD (1) · Leo I. Gordon, MD (1) · Marie T. Fallon (1) · Martine Bagot, MD (1)
PMID 32632956, PMID 15459300, PMID 16148284, PMID 16710026, PMID 17397698, PMID 22480131, PMID 22924950, PMID 26700120, PMID 26700123, PMID 27020837, PMID 28600132, PMID 28935847, PMID 30892603, PMID 31526286, PMID 32502876, PMID 32850876, PMID 33794441, PMID 34507350, PMID 35857290
2004 (1), 2009 (1), P30CA015083 (1), P30CA068485 (1), P30CA069533 (1), R01CA127655 (1)